Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
3.
Antiviral Res ; 194: 105158, 2021 10.
Article in English | MEDLINE | ID: covidwho-1340541

ABSTRACT

It is more than 20 years since the neuraminidase inhibitors, oseltamivir and zanamivir were approved for the treatment and prevention of influenza. Guidelines for global surveillance and methods for evaluating resistance were established initially by the Neuraminidase Inhibitor Susceptibility Network (NISN), which merged 10 years ago with the International Society for influenza and other Respiratory Virus Diseases (isirv) to become the isirv-Antiviral Group (isirv-AVG). With the ongoing development of new influenza polymerase inhibitors and recent approval of baloxavir marboxil, the isirv-AVG held a closed meeting in August 2019 to discuss the impact of resistance to these inhibitors. Following this meeting and review of the current literature, this article is intended to summarize current knowledge regarding the clinical impact of resistance to polymerase inhibitors and approaches for surveillance and methods for laboratory evaluation of resistance, both in vitro and in animal models. We highlight limitations and gaps in current knowledge and suggest some strategies for addressing these gaps, including the need for additional clinical studies of influenza antiviral drug combinations. Lessons learned from influenza resistance monitoring may also be helpful for establishing future drug susceptibility surveillance and testing for SARS-CoV-2.


Subject(s)
Antiviral Agents/therapeutic use , Influenza, Human/drug therapy , Animals , Antiviral Agents/adverse effects , Antiviral Agents/pharmacology , Dibenzothiepins/pharmacology , Drug Resistance, Viral , Enzyme Inhibitors/pharmacology , Humans , Influenza, Human/virology , Knowledge , Morpholines/pharmacology , Neuraminidase/therapeutic use , Oseltamivir/pharmacology , Pyridones/pharmacology , SARS-CoV-2/drug effects , Triazines/pharmacology , Virus Replication/drug effects , Zanamivir/pharmacology
4.
Influenza Other Respir Viruses ; 15(4): 488-494, 2021 07.
Article in English | MEDLINE | ID: covidwho-1132956

ABSTRACT

BACKGROUND: Coronavirus disease (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first detected in Japan in January 2020 and has spread throughout the country. Previous studies have reported that viral interference among influenza virus, rhinovirus, and other respiratory viruses can affect viral infections at the host and population level. METHODS: To investigate the impact of COVID-19 on influenza and other respiratory virus infections, we analyzed clinical specimens collected from 2244 patients in Japan with respiratory diseases between January 2018 and September 2020. RESULTS: The frequency of influenza and other respiratory viruses (coxsackievirus A and B; echovirus; enterovirus; human coronavirus 229E, HKU1, NL63, and OC43; human metapneumovirus; human parainfluenza virus 1, 2, 3, and 4; human parechovirus; human respiratory syncytial virus; human adenovirus; human bocavirus; human parvovirus B19; herpes simplex virus type 1; and varicella-zoster virus) was appreciably reduced among all patients during the COVID-19 pandemic except for that of rhinovirus in children younger than 10 years, which was appreciably increased. COVID-19 has not spread among this age group, suggesting an increased risk of rhinovirus infection in children. CONCLUSIONS: Rhinovirus infections should be continuously monitored to understand their increased risk during the COVID-19 pandemic and viral interference with SARS-CoV-2.


Subject(s)
COVID-19/epidemiology , Picornaviridae Infections/epidemiology , Rhinovirus/isolation & purification , Adult , Child , Child, Preschool , Coinfection/diagnosis , Coinfection/epidemiology , Coinfection/virology , Female , Humans , Infant , Infant, Newborn , Japan/epidemiology , Male , Picornaviridae Infections/diagnosis , Picornaviridae Infections/virology , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/virology , Risk , SARS-CoV-2 , Virus Diseases/diagnosis , Virus Diseases/epidemiology , Virus Diseases/virology , Viruses/isolation & purification
SELECTION OF CITATIONS
SEARCH DETAIL